Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07132190 · ClinicalTrials.gov registry record · Phase 2
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
A Phase 2 study of Brain Metastases, Adult and Brain Tumor - Metastatic, sponsored by Ayal A. Aizer, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07132190 is a Phase 2 study of Brain Metastases, Adult and Brain Tumor - Metastatic that is actively recruiting participants, run by Ayal A. Aizer, MD. The registered enrollment target is 60 participants, below the 92-participant average among 14 other Brain Metastases, Adult trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07132190, a Phase 2 study of Brain Metastases, Adult and Brain Tumor - Metastatic, is actively recruiting participants, sponsored by Ayal A. Aizer, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation treatment. The intent of this shorter time interval is to increase the likelihood that the brain metastases being treated remain fully within the high-dose radiation fields. Participants will be randomized to receive brain-directed stereotactic radiation with a 1mm margin or 0mm margin, have their simulation/radiation planning imaging on the same day that brain-directed stereotactic radiation is delivered, and have repeat simulation/radiation planning scans during the course of treatment if more than 2-3 days have elapsed since the most recent scans.
Conditions Studied
Interventions
- RADIATION Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital / Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-12-30 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07132190
The ClinicalTrials.gov registry entry for NCT07132190 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 14 other Brain Metastases, Adult trials with a reported enrollment target (35% lower). The listed sponsor is Ayal A. Aizer, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Brain Metastases, Adult appearing as the primary indexed condition, and to 1 intervention - of which Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV is the first listed.
NCT07132190 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07132190 about?
NCT07132190 is a clinical study titled "Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction". The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation treatment. The intent of this shorter time interval is to increase the likelihoo...
What is the current status of trial NCT07132190?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-12-30. Estimated completion is 2029-09.
What conditions does trial NCT07132190 study?
This clinical trial studies the following conditions: Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors.
What interventions are being tested in trial NCT07132190?
The interventions under investigation include: Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV (RADIATION).
Who is sponsoring clinical trial NCT07132190?
This trial is sponsored by Ayal A. Aizer, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07132190 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
RECRUITING · Phase 2
-
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
RECRUITING · Phase 2
-
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Multi-disciplinary Care for Brain Metastases
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.